Live from AUA2022: Highlights in Overactive Bladder

Live from AUA2022: Highlights in Overactive Bladder is a panel discussion filmed during the 2022 AUA Annual Meeting!

This activity is designed to increase the urologist’s understanding of how to translate the latest scientific advances into their routine clinical practice, improving the care of patients with OAB. Faculty will review currently available agents as well as third line therapies, including the pros and cons of each option, and the current data regarding outcomes to facilitate proper patient counseling. Patient communication, including goal setting with respect to realistic expectations of therapy and therapeutic algorithms are important factors in improving patient outcomes.


Acknowledgements

This educational activity is supported by an independent educational grant from:

  • Urovant Sciences, Inc.

Target Audience

  • Urologists

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Define the similarities and differences between the various oral pharmacotherapies for OAB and discuss the potential future pharmacological pathways and therapies.
  2. Describe the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.
  3. Discuss optimal use of third line therapies in order to maximize clinical benefit.
  4. Counsel patients on the pros and cons and risks and benefits of each of the third line therapies for OAB.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Course opens: 
05/15/2022
Course expires: 
05/15/2023
Rating: 
0

Faculty disclosures will be posted here prior to the start of the course.

 

Education Council Disclosures

PDF iconEducation Council Disclosures

COI Review Work Group Disclosures

PDF iconCOI Review Work Group Disclosures

 

AUA Office of Education Staff has nothing to disclose.

All relevant financial relationships have been mitigated.

Course Director(s)

David Ginsberg, MD

has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Avation;.
has a financial relationship (Consultant or Advisor (General Urology)) with Urovant;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with Caldera;.
Faculty(s)

Sara Lenherr, MD, MS

has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Department of Defense (DoD);.

Anne Pelletier Cameron, MD

has a financial relationship (Meeting Participant or Lecturer (Female Pelvic Medicine & Reconstructive Surgery)) with Wellspect;.

Eric Rovner, MD

has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Medtronics;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with Urovant;.
has a financial relationship (Investment Interest (Specialty Not Specified)) with NextMed;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Bluewind;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Hologix;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Allergan;.
has a financial relationship (Scientific Study or Trial (Specialty Not Specified)) with NIH/NIDDK;.
has a financial relationship (Consultant or Advisor (Female Pelvic Medicine & Reconstructive Surgery)) with astellas;.
has a financial relationship (Consultant or Advisor (Specialty Not Specified)) with Valencia;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and/or listening to the podcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 1.0 hours

Release Date:  May, 2022
Expiration Date: May, 2023

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Non-Physician Participation
Please login or register to take this course.

Registration for this course is complimentary. 


AUA PARTICIPANT INFORMATION & POLICIES

Disclaimer:

The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Reproduction Permission:

Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.

Special Assistance: 

The AUA complies with the Americans with Disabilities Act §12112(a). If any participant is in need of special assistance, please contact Education@AUAnet.org.